Oncol Res Treat. 2018;41(12):762-768. doi: 10.1159/000492343. Epub 2018 Nov 21.
The role of microRNA-133a (miR-133a) in non-small cell lung cancers (NSCLCs) is controversial. Thus, we conducted a comprehensive study based on meta-analysis and The Cancer Genome Atlas (TCGA) database.
Publications were searched in both English and Chinese databases, and meta-analysis was performed using Stata 12.0. The clinical value of miR-133a in NSCLC was investigated by collecting and calculating data from the TCGA database, and the statistical analysis was performed in R 3.5.0.
5 studies with 364 cases were included in this meta-analysis. The combined pooled result showed that high expression of miR-133a was associated with a favorable survival outcome in NSCLC patients (hazard ratio 0.561, 95% confidence interval 0.396-0.794, p = 0.001). Meanwhile, a total of 984 NSCLC patients were extracted from the TCGA database. Results showed an area under the ROC curve value for miR-133a-3p of 0.902, and the expression of miR-133a-3p was linked with clinicopathologic parameters of NSCLC (p < 0.05), including sex, age, social status, and lymph node metastasis.
Our study indicated that miR-133a might act as a tumor suppressor and be a valuable independent prognostic and diagnostic biomarker for NSCLC, and NSCLC patients with high expression of miR-133 might have a better prognosis.
微小 RNA-133a（miR-133a）在非小细胞肺癌（NSCLC）中的作用存在争议。因此，我们基于荟萃分析和癌症基因组图谱（TCGA）数据库进行了全面研究。
在中英文数据库中进行了文献检索，并使用 Stata 12.0 进行荟萃分析。通过从 TCGA 数据库中收集和计算数据，研究 miR-133a 在 NSCLC 中的临床价值，并在 R 3.5.0 中进行统计分析。
该荟萃分析纳入了 5 项研究共 364 例患者。合并后的汇总结果表明，miR-133a 高表达与 NSCLC 患者的生存结局良好相关（风险比 0.561，95%置信区间 0.396-0.794，p = 0.001）。同时，从 TCGA 数据库中提取了 984 例 NSCLC 患者。结果显示 miR-133a-3p 的 ROC 曲线下面积值为 0.902，miR-133a-3p 的表达与 NSCLC 的临床病理参数相关（p < 0.05），包括性别、年龄、社会地位和淋巴结转移。
本研究表明，miR-133a 可能作为一种肿瘤抑制因子发挥作用，是 NSCLC 有价值的独立预后和诊断生物标志物，miR-133a 高表达的 NSCLC 患者可能具有更好的预后。
